Dr. Parikh on the Significance of the CLL-IPI

Video

In Partnership With:

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).

One of the most important contributions to the landscape of CLL has been the development of the CLL-IPI, Parikh explains. This combines 5 different factors, including age, clinical stage, TP53 mutation status, IGVH mutation status, and serum β2-microglobulin concentration.

The CLL-IPI allows physicians to prognosticate when patients are going to require therapy for their CLL. This is especially emphasized for all patients with CLL, specifically those who are newly diagnosed.

Related Videos
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Kian-Huat Lim, MD, PhD
Joaquim Bellmunt, MD, PhD
Stephen V. Liu, MD
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD